

04-22-04

EXPRESS MAIL CERTIFICATE

"Express Mail" mailing label number : EL 984 914 631 US

Date of Deposit : April 21, 2004

Type of Documents : Information Disclosure Statement (2 pages);
Form PTO-1449 (1 page) with References:
10 Other Documents;

and Return Postcard

Serial No. : 10/659,789

Filing Date : September 10, 2003

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and are addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Diane H. Marshall (signature)
Diane H. Marshall



PATENTS
EL 984 914 631 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Stenland, *et al.* : Examiner: To be assigned
Serial No.: 10/659,789 : Art Unit: 1645
Filed: September 10, 2003 : Docket No.: B185 1210.1
(MSC 8015)

For: **PRION CLEARANCE USING PARTICULATE METAL OXIDES**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants hereby voluntarily disclose the references listed on the attached Form PTO-1449 to the Commissioner for Patents. Copies of ten (10) references (D1-D10) listed on Applicants' form PTO-1449 are enclosed herewith. This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits of the application. Accordingly, no fees are due. However, should any fee be due in connection with this submission, the Commissioner is hereby authorized to charge those fees to Deposit Account No. **09-0528**.


This statement should not be construed as the representation that any search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of all available information, and to form independent opinions as to its significance.

Applicants further reserve the right to establish the patentability of the claimed invention over any of the listed information should they be applied as references, and/or to prove that the cited information may not be prior art, and/or to prove that the cited information may not be enabling for the teachings they purport to offer.

The Examiner is respectfully requested to initial and return copies of the enclosed Form PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

Respectfully submitted,


Date: April 20, 2004



Carl B. Massey, Jr.
Registration No. 44,224
Attorney for Applicants

Docket: **B185 1210.1 (MSC 8015)**

Womble Carlyle Sandridge & Rice, PLLC
Post Office Box 7037
Atlanta, Georgia 30357-00378
Telephone (336) 721-3681
Facsimile(336) 726-8074



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DKT NO.
B185 1210.1

SERIAL NO.
10/659,789

APPLICANT
Stenland, et al.

FILING DATE
09/10/03

GROUP
1645

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CL.	SUBCL.	FILING DATE IF APPROP.
	P1	US 2002/0192794 A1	12/19/02	Dadd, et al.	435	217	
	P2	6,437,102	08/20/02	Lee, et al.	530	412	
	P3	5,290,703	03/01/94	Hsu, et al.	436	71	
	P4	5,141,872	08/25/92	Tamir, I.	436	71	
	P5	5,085,784	02/04/92	Ostreicher, E.A.	210	767	
	P6	2,390,074	12/04/45	Cohn, E.J.	260	122	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CL.	SUBCL	TRANSLATION

OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)

	D1	Alpers, M.P., "Epidemiology and Ecology of Kuru," Vol. 1, pp. 67-90, in <i>Slow Transmissible Diseases of the Nervous System</i> , Academic Press, Inc., publisher, S. B. Prusiner and W. J. Hadlow, editors (1979).
	D2	Bolton, D.C., et al., "Isolation and Structural Studies of the Intact Scrapie Agent Protein," <i>Arch. Biochem. Biophys.</i> , 258(2): 579-590 (1987).
	D3	Brown, P., et al., "'Friendly Fire' in medicine: hormones, homografts, and Creutzfeldt-Jakob disease," <i>Lancet</i> , 340(8810): 24-27 (1992).
	D4	Brown, P., et al., "The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy," <i>Transfusion</i> , 38(9): 810-816 (1998).
	D5	Chazot, G., et al., "New Variant of Creutzfeldt-Jakob disease in a 26-year-old French man," <i>Lancet</i> , 347(9009): 1181 (1996).
	D6	Lee, D.C., et al., "Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein," <i>J. Virol. Methods</i> , 84: 77-89 (2000).
	D7	Lee, D.C., et al., "A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins," <i>Transfusion</i> , 41(4): 449-455 (2001).
	D8	Prusiner, S.B., "Molecular Biology of Prion Diseases," <i>Science</i> , 252: 1515-1522 (1991).
	D9	Stenland, C.J., et al., "Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma," <i>Transfusion</i> , 42(11): 1497-1500 (2002).
	D10	Will, R.G., et al., "A new variant of Creutzfeldt-Jakob Disease in the UK," <i>Lancet</i> , 347(9006): 921-925 (1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.